Noradrenalină Amdipharm (Noradrenaline Tartrate)

Noradrenaline Tartrate stimulates alpha‑1 adrenergic receptors on vascular smooth muscle, causing vasoconstriction, and modestly activates beta‑1 receptors, increasing cardiac contractility. This dual action elevates arterial pressure and improves organ perfusion.

The dosing regimen for Noradrenalină Amdipharm is determined by the prescribing clinician based on the patient’s hemodynamic status, target blood pressure, and response to therapy. No fixed dose is provided here.

Safety data for Noradrenalină Amdipharm in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under strict medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Noradrenalină Amdipharm is the first‑line vasopressor for most shock states due to its potent alpha‑1 activity and modest beta‑1 effect. Compared with dopamine or phenylephrine, it offers more predictable blood‑pressure control with fewer tachyarrhythmic events, making it preferred in septic shock and cardiac arrest.

The product must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen. Before use, inspect the vial for particulate matter and ensure the solution is at room temperature if required for infusion.

Noradrenalină Amdipharm is given intravenously, typically as a continuous infusion. The drug is diluted in an appropriate carrier solution and administered via a calibrated infusion pump, allowing precise titration to achieve the desired blood‑pressure target.

Serious risks include severe hypertension, myocardial ischemia, life‑threatening arrhythmias, peripheral tissue necrosis at the infusion site, and rare anaphylactic reactions. Continuous hemodynamic and cardiac monitoring is essential to detect these events promptly.

Patients with known hypersensitivity to norepinephrine or any excipients, those with uncontrolled severe hypertension, or individuals in whom vasoconstriction could worsen tissue perfusion (e.g., severe peripheral vascular disease) should not receive this medication.